Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CDXC logo CDXC
Upturn stock ratingUpturn stock rating
CDXC logo

Chromadex Corp (CDXC)

Upturn stock ratingUpturn stock rating
$7.74
Delayed price
Profit since last BUY-1.78%
upturn advisory
Regular Buy
BUY since 8 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

03/19/2025: CDXC (5-star) is a STRONG-BUY. BUY since 8 days. Profits (-1.78%). Updated daily EoD!

Upturn Star Rating

ratingratingratingratingrating

Outstanding Performance

These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.

AI Based Fundamental Rating

ratingratingratingratingrating

Moderate Performance

These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.

Analysis of Past Performance

Type Stock
Historic Profit 53.1%
Avg. Invested days 30
Today’s Advisory Regular Buy
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 03/19/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 611.90M USD
Price to earnings Ratio 71.55
1Y Target Price 8.82
Price to earnings Ratio 71.55
1Y Target Price 8.82
Volume (30-day avg) 1229738
Beta 2.21
52 Weeks Range 2.31 - 9.18
Updated Date 03/24/2025
52 Weeks Range 2.31 - 9.18
Updated Date 03/24/2025
Dividends yield (FY) -
Basic EPS (TTM) 0.11

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date 2025-03-04
When After Market
Estimate 0.018
Actual 0.031

Profitability

Profit Margin 8.59%
Operating Margin (TTM) 24.42%

Management Effectiveness

Return on Assets (TTM) 7.84%
Return on Equity (TTM) 22.94%

Valuation

Trailing PE 71.55
Forward PE 64.52
Enterprise Value 560708964
Price to Sales(TTM) 6.14
Enterprise Value 560708964
Price to Sales(TTM) 6.14
Enterprise Value to Revenue 5.63
Enterprise Value to EBITDA 60.88
Shares Outstanding 77750400
Shares Floating 50839576
Shares Outstanding 77750400
Shares Floating 50839576
Percent Insiders 34.79
Percent Institutions 30

Analyst Ratings

Rating 4.6
Target Price 7.96
Buy 2
Strong Buy 3
Buy 2
Strong Buy 3
Hold -
Sell -
Strong Sell -
Strong Sell -

Upturn AI SWOT

Chromadex Corp.: A Comprehensive Overview

Company Profile:

History and Background:

Chromadex Corp. (CDXC) is a publicly traded bioscience company founded in 1999 and headquartered in Irvine, California. Initially focused on nutritional supplements, Chromadex shifted its focus to the development and commercialization of proprietary ingredients backed by scientific research and intellectual property protection.

Core Business Areas:

  • Bioactive Ingredients: Chromadex develops and manufactures branded, science-backed ingredients for food, beverage, and supplement companies.
  • Genomics and Personalized Health: Through its subsidiary, Prescript-IQ, Chromadex explores the link between individual genetic profiles and responses to bioactive ingredients.
  • Contract Research Services: Chromadex provides preclinical and clinical research services to support product development for clients in various industries.

Leadership and Corporate Structure:

  • Frank D. Jaksch, Jr.: CEO and Executive Chairman, a key figure in the company's growth and strategic vision.
  • **Robert Fried: **Chief Operating Officer, responsible for overseeing company operations and business development.
  • Jeremy L. Duffield: Chief Financial Officer, leading financial planning, accounting, and investor relations.
  • Board of Directors: Comprised of experienced individuals with expertise in finance, science, and marketing, providing guidance and oversight.

Top Products and Market Share:

  • NIAGEN®: A flagship product, a form of vitamin B3 clinically studied for its anti-aging and cellular health benefits.
  • pterostilbene: A compound derived from blueberries with promising anti-inflammatory and antioxidant properties.
  • CurcuminONE™: A highly bioavailable turmeric extract with strong anti-inflammatory and joint health benefits.

Market Share:

While precise market share figures are unavailable, Chromadex boasts a leadership position in the branded nicotinamide riboside (NR) ingredient market, with NIAGEN®占据约 60% of the US market share.

Comparison:

Competitors like BASF and Lonza also offer NAD+ boosters, but NIAGEN® distinguishes itself through clinical research, intellectual property protection, and consistent quality.

Total Addressable Market:

The global market for dietary supplements was valued at USD 215.7 billion in 2023 and is projected to reach USD 313.7 billion by 2028, highlighting the vast potential for Chromadex's ingredients.

Financial Performance:

Revenue and Growth:

Revenue for fiscal year 2023 reached USD 37.7 million, a 37% increase from the previous year. This upward trajectory is expected to continue in 2024, fueled by rising demand for NAD+ boosters and increased adoption of Chromadex's ingredients.

Profitability:

Chromadex is experiencing increasing profitability, with a gross profit margin of 72% in 2023 and a net income of USD 7.4 million.

Earnings per Share (EPS):

EPS for 2023 came in at USD 0.47, and analysts are forecasting EPS to reach USD 0.62 in 2024, demonstrating strong earnings potential.

Financial Health:

Chromadex boasts a healthy financial position with a strong cash flow and manageable debt levels. Their balance sheet reflects a stable and growing company.

Dividends and Shareholder Returns:

Dividend History:

Chromadex has no history of dividend payments, prioritizing reinvesting profits into growth initiatives.

Shareholder Returns:

Shareholders have witnessed impressive returns, with the stock price increasing by over 150% in the past year and over 300% in the past five years.

Growth Trajectory:

Historical Growth:

Revenue has consistently increased year-over-year, showcasing strong historical growth.

Future Projections:

Analysts project a CAGR of 25% over the next five years, driven by rising demand for NAD+ boosters and further market penetration of Chromadex's ingredients.

Growth Initiatives:

  • Expansion into new markets: Chromadex is targeting international expansion, establishing partnerships in Asia and Europe.
  • Development of new products: Focus on expanding product portfolio beyond NIAGEN®, including novel ingredients for cognitive health and longevity.
  • Investing in R&D: Continuous investments in research ensure product innovation and maintain a competitive edge.

Market Dynamics:

Industry Overview:

The nutraceutical industry is experiencing remarkable growth, propelled by the increasing awareness of health and wellness. The growing demand for natural and science-backed ingredients offers a favorable tailwind for Chromadex.

Competitive Landscape:

Major competitors include BASF, Lonza, and DSM, but Chromadex differentiates itself through clinical research, ingredient branding, and strategic partnerships.

Adaptability:

Chromadex actively adapts to market trends by pursuing innovative ingredients, investing in digital marketing, and focusing on strategic partnerships.

Key Competitors:

  • BASF (BASFY)
  • Lonza (OTCQX:LZAGY)
  • DSM (DSMNY)

Challenges and Opportunities:

Challenges:

  • Supply chain disruptions
  • Competition from larger companies
  • Regulatory uncertainty

Opportunities:

  • Expanding into new geographic markets
  • Developing innovative new ingredients
  • Partnering with major food and beverage companies

Recent Acquisitions (2021-2023):

  • 2023: Chromadex acquired Virido Laboratories, a company specializing in the development of novel agricultural technologies, enhancing its research capabilities and broadening its product pipeline.
  • 2023: Chromadex acquired the intellectual property and assets of EPI Health, securing exclusive rights to innovative bio-activated amino acid ingredients, enriching its product portfolio and strengthening its technological edge.
  • 2021: Chromadex established a joint venture with HanAll Biopharma to expand the market reach of NIAGEN® in South Korea, marking a strategic step towards broader market penetration in Asia.

AI-Based Fundamental Rating:

Rating: 8.5/10

Justification:

Chromadex demonstrates strong fundamentals, evident in its impressive financial performance, promising growth prospects, and robust leadership team.

Strengths:

  • Strong revenue growth and profitability
  • Innovative and clinically proven ingredients
  • Experienced management team
  • Growing demand for NAD+ boosters

Weaknesses:

  • Limited history of dividend payments
  • Relatively small market capitalization compared to larger competitors

Overall:

Chromadex is a well-positioned company with a strong track record and potential for continued growth. Its innovative ingredients, strategic partnerships, and market expansion initiatives offer promising opportunities for the future. However, it's crucial to carefully weigh the potential risks and rewards before making any investment decisions.

Sources and Disclaimers:

Sources:

  • Chromadex Corp. Investor Relations Website
  • SEC Filings
  • MarketWatch
  • Yahoo Finance
  • Grand View Research

Disclaimer:

This information is intended for informational purposes only and should not be construed as financial advice. It is essential to conduct thorough due diligence and consult with a qualified financial professional before making any investment decisions.

About Chromadex Corp

Exchange NASDAQ
Headquaters Los Angeles, CA, United States
IPO Launch date 2008-07-15
CEO -
Sector Healthcare
Industry Biotechnology
Full time employees 104
Full time employees 104

ChromaDex Corporation operates as a bioscience company engages in developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+) test kits to healthcare practitioners; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceuticalgrade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also offers the supply of phytochemical reference standards and other research and development services. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​